Search Results - Jon Curwen

  • Showing 1 - 10 results of 10
Refine Results
  1. 1
    Role of the endothelin axis and its antagonists in the treatment of cancer

    Role of the endothelin axis and its antagonists in the treatment of cancer by Anna Bagnato, Marilena Loizidou, B R Pflug, Jon Curwen, J Growcott

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence

    Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence by Clive Morris, Alyssa Rose, Jon Curwen, Andrew Hughes, David J. Wilson, Duncan Webb

    Published 2005
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

    Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the... by Jon Curwen, Helen Musgrove, Jane Kendrew, Graham H.P. Richmond, Donald Ogilvie, Stephen R. Wedge

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib

    In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib by Michael G. Rolf, Jon Curwen, Margaret H. Veldman-Jones, Cath Eberlein, Jianyan Wang, Alex Harmer, Caroline J. Hellawell, Martin Braddock

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation

    The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation by Matthew Skinner, Karen Philp, David Lengel, Lucy C. Coverley, Eva Lamm Bergström, Philip Glaves, Helen Musgrove, Helen Prior, Martin Braddock, R. Huby, Jon Curwen, Paul Duffy, Alexander R. Harmer

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer

    Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer by Chrysiis Michaloglou, Claire Crafter, Rasmus Siersbæk, Oona Delpuech, Jon Curwen, Larissa S. Carnevalli, Anna D. Staniszewska, Urszula M. Polanska, Azadeh Cheraghchi-Bashi, Mandy Lawson, Igor Chernukhin, Robert McEwen, Jason S. Carroll, Sabina Cosulich

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

    AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules by Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D’Cruz, James Yates, Michael Grondine, Zoë Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina Cosulich

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

    Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 by Tim P. Green, Mike Fennell, Robin Whittaker, Jon Curwen, Vivien N. Jacobs, J M Allen, Armelle Logié, Judith Hargreaves, D. Mark Hickinson, Robert W. Wilkinson, Paul Elvin, Brigitte Boyer, Neil O. Carragher, Patrick A. Plé, Alun Bermingham, Geoffrey A. Holdgate, Walter H.J. Ward, Laurent Hennequin, Barry R. Davies, Gerard Costello

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

    AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer by Stephen R. Wedge, Jane Kendrew, Laurent Hennequin, Paula J. Valentine, Simon T. Barry, Sandra R. Brave, Neil R. Smith, Neil H. James, Michael Dukes, Jon Curwen, Rosemary Chester, Janet A. Jackson, Sarah J. Boffey, Lyndsey L. Kilburn, Sharon Barnett, Graham H.P. Richmond, P.F. Wadsworth, Mike Walker, Alison Bigley, Sian Taylor, Lee Cooper, Sarah Beck, Juliane M. Jürgensmeier, Donald Ogilvie

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and<i>ESR1</i>-Mutant Breast Tumors in Preclinical Models

    AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and<i>ESR1</i>-Mutant Breast Tumors in Preclinical Models by Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena Callis, Jon Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J. Feron, Galith Karoutchi, Philip A. MacFaul, Tom Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth M. Davies, Graeme E. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, C Sadler, Graham H.P. Richmond, Brendon Ladd, Ermira Pazolli, Anne Marie Mazzola, Celina M. D’Cruz, Chris De Savi

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: